Amarantus BioSciences, Inc. to Evaluate LymPro Test as a Diagnostic and Prognostic for Chronic Traumatic Encephalopathy
6/21/2013 10:40:58 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SUNNYVALE, Calif.--(BUSINESS WIRE)--Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis, today announced that it plans to evaluate its LymPro Test® as a potential diagnostic and prognostic for Chronic Traumatic Encephalopathy (CTE). “The scientific basis of cell-cycle dysfunction that underpins the rationale for development of the LymPro Test as a diagnostic blood test for Alzheimer’s disease may also be utilized to diagnose CTE in populations that have been subjected to multiple head injuries and possibly even identify individuals who are pre-disposed to developing CTE before they engage in activities likely to subject them to multiple head injuries,” said Dr. John W. Commissiong, Chief Scientific Officer of Amarantus. “As a blood test, LymPro would have significant advantages over other more complex and expensive diagnostic alternatives, in particular the ability to detect the onset of CTE at an early stage. We plan to begin the evaluation process in the second half of 2013 by conducting a small proof-of-concept clinical study in addition to our planned Alzheimer’s studies.”
Help employers find you! Check out all the jobs and post your resume.